cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines

We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 37; H. 5; S. 463
Hauptverfasser:	Ormerod, M G, O'Neill, C, Robertson, D, Kelland, L R, Harrap, K R
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Germany 1996
Schlagworte:	Antineoplastic Agents - pharmacology Apoptosis Cell Adhesion - drug effects Cell Death Cisplatin - pharmacology DNA, Neoplasm - analysis DNA, Neoplasm - metabolism Drug Resistance, Neoplasm Electrophoresis, Agar Gel Female Flow Cytometry Humans Ovarian Neoplasms - pathology S Phase - drug effects Tumor Cells, Cultured
ISSN:	0344-5704
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50% inhibitory concentrations (IC50 values) after a 2-h exposure to the drug are: CH1, 2.5 microM; CH1cisR, 7.5 microM; and SKOV-3, 33 microM. Despite the variation in sensitivity, the amount of Pt bound to DNA and the rate of removal of Pt was similar for the three lines. There were significant differences in the rates of formation of DNA cross-links but these were not large enough to account for the high resistance of the SKOV-3 line. We have reported that in the L1210 murine leukaemia cell line there are two mechanisms of cisplatin-induced cell death - one of which involves apoptosis. In this paper, we report on an investigation into whether sensitivity to apoptosis played a role in the resistance of these ovarian lines toward cisplatin. After a 2-h incubation with the drug, cells from the three lines showed evidence of death through apoptosis. The cells detached from the culture dish in a time- and dose-dependent fashion. These cells morphologically were quite distinctive from the attached cells and showed changes in their chromatin structure indicative of apoptosis. Their DNA had not been degraded into oligonucleosomal fragments (200 bp and multiples thereof) but had been cut into larger fragments (30 kilobase pairs, kbp) of a size associated with chromatin domains (chromatin loops). At equitoxic doses of drug, the quantity of cells undergoing apoptosis was similar for the three cell lines. The most prominent effect on cell-cycle kinetics was a slowdown in S-phase transit during which the cells underwent apoptosis. Cells that successfully completed the S phase subsequently suffered a temporary G2 block. We propose that the sensitivity of these cell lines to cisplatin was governed by their ability to handle damage caused by platination of the DNA and that the major mechanism of cisplatin-induced cell death in all three cell lines was the induction of apoptosis.
AbstractList	We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50% inhibitory concentrations (IC50 values) after a 2-h exposure to the drug are: CH1, 2.5 microM; CH1cisR, 7.5 microM; and SKOV-3, 33 microM. Despite the variation in sensitivity, the amount of Pt bound to DNA and the rate of removal of Pt was similar for the three lines. There were significant differences in the rates of formation of DNA cross-links but these were not large enough to account for the high resistance of the SKOV-3 line. We have reported that in the L1210 murine leukaemia cell line there are two mechanisms of cisplatin-induced cell death - one of which involves apoptosis. In this paper, we report on an investigation into whether sensitivity to apoptosis played a role in the resistance of these ovarian lines toward cisplatin. After a 2-h incubation with the drug, cells from the three lines showed evidence of death through apoptosis. The cells detached from the culture dish in a time- and dose-dependent fashion. These cells morphologically were quite distinctive from the attached cells and showed changes in their chromatin structure indicative of apoptosis. Their DNA had not been degraded into oligonucleosomal fragments (200 bp and multiples thereof) but had been cut into larger fragments (30 kilobase pairs, kbp) of a size associated with chromatin domains (chromatin loops). At equitoxic doses of drug, the quantity of cells undergoing apoptosis was similar for the three cell lines. The most prominent effect on cell-cycle kinetics was a slowdown in S-phase transit during which the cells underwent apoptosis. Cells that successfully completed the S phase subsequently suffered a temporary G2 block. We propose that the sensitivity of these cell lines to cisplatin was governed by their ability to handle damage caused by platination of the DNA and that the major mechanism of cisplatin-induced cell death in all three cell lines was the induction of apoptosis.We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50% inhibitory concentrations (IC50 values) after a 2-h exposure to the drug are: CH1, 2.5 microM; CH1cisR, 7.5 microM; and SKOV-3, 33 microM. Despite the variation in sensitivity, the amount of Pt bound to DNA and the rate of removal of Pt was similar for the three lines. There were significant differences in the rates of formation of DNA cross-links but these were not large enough to account for the high resistance of the SKOV-3 line. We have reported that in the L1210 murine leukaemia cell line there are two mechanisms of cisplatin-induced cell death - one of which involves apoptosis. In this paper, we report on an investigation into whether sensitivity to apoptosis played a role in the resistance of these ovarian lines toward cisplatin. After a 2-h incubation with the drug, cells from the three lines showed evidence of death through apoptosis. The cells detached from the culture dish in a time- and dose-dependent fashion. These cells morphologically were quite distinctive from the attached cells and showed changes in their chromatin structure indicative of apoptosis. Their DNA had not been degraded into oligonucleosomal fragments (200 bp and multiples thereof) but had been cut into larger fragments (30 kilobase pairs, kbp) of a size associated with chromatin domains (chromatin loops). At equitoxic doses of drug, the quantity of cells undergoing apoptosis was similar for the three cell lines. The most prominent effect on cell-cycle kinetics was a slowdown in S-phase transit during which the cells underwent apoptosis. Cells that successfully completed the S phase subsequently suffered a temporary G2 block. We propose that the sensitivity of these cell lines to cisplatin was governed by their ability to handle damage caused by platination of the DNA and that the major mechanism of cisplatin-induced cell death in all three cell lines was the induction of apoptosis. We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50% inhibitory concentrations (IC50 values) after a 2-h exposure to the drug are: CH1, 2.5 microM; CH1cisR, 7.5 microM; and SKOV-3, 33 microM. Despite the variation in sensitivity, the amount of Pt bound to DNA and the rate of removal of Pt was similar for the three lines. There were significant differences in the rates of formation of DNA cross-links but these were not large enough to account for the high resistance of the SKOV-3 line. We have reported that in the L1210 murine leukaemia cell line there are two mechanisms of cisplatin-induced cell death - one of which involves apoptosis. In this paper, we report on an investigation into whether sensitivity to apoptosis played a role in the resistance of these ovarian lines toward cisplatin. After a 2-h incubation with the drug, cells from the three lines showed evidence of death through apoptosis. The cells detached from the culture dish in a time- and dose-dependent fashion. These cells morphologically were quite distinctive from the attached cells and showed changes in their chromatin structure indicative of apoptosis. Their DNA had not been degraded into oligonucleosomal fragments (200 bp and multiples thereof) but had been cut into larger fragments (30 kilobase pairs, kbp) of a size associated with chromatin domains (chromatin loops). At equitoxic doses of drug, the quantity of cells undergoing apoptosis was similar for the three cell lines. The most prominent effect on cell-cycle kinetics was a slowdown in S-phase transit during which the cells underwent apoptosis. Cells that successfully completed the S phase subsequently suffered a temporary G2 block. We propose that the sensitivity of these cell lines to cisplatin was governed by their ability to handle damage caused by platination of the DNA and that the major mechanism of cisplatin-induced cell death in all three cell lines was the induction of apoptosis.
Author	Robertson, D Ormerod, M G O'Neill, C Kelland, L R Harrap, K R
Author_xml	– sequence: 1 givenname: M G surname: Ormerod fullname: Ormerod, M G organization: Cancer Research Campaign Centre For Cancer Therapeutics, Institute of Cancer Research, Royal Cancer Hospital, Sutton, UK – sequence: 2 givenname: C surname: O'Neill fullname: O'Neill, C – sequence: 3 givenname: D surname: Robertson fullname: Robertson, D – sequence: 4 givenname: L R surname: Kelland fullname: Kelland, L R – sequence: 5 givenname: K R surname: Harrap fullname: Harrap, K R
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/8599870$$D View this record in MEDLINE/PubMed
BookMark	eNotUD1PwzAU9FBU2sLIiOQJwRCwHSdORtTyUakSC8yRa78Qo9gOtlOJmT9OUDuddHfv7vSWaOa8A4SuKLmnhIiHSAirCCEF4TSfoQXJOc8KQfg5Wsb4NSkTn8_RvCrquhJkgX6VidnGSGuNA21U1_vgh14m40Z7u93eZcbpUYHGCvoea5Cpw6kLfvzssBz8kHw0ERuHI7hokjkAlk7jABOdpEu4G6102B9kMBMqGZRx3spjXj-1xgt01so-wuUJV-jj-el9_Zrt3l6268ddpnIqUiYYq6BSvGxbVoOsFSO6qHTbKsFrXSpWtozqUlBeCSoo5PtCsOlUcUlqzTRboZtj7hD89wgxNdbE_xnSgR9jI0Rd5jQvJ-P1yTjuLehmCMbK8NOcvsb-AA4tcPk
CitedBy_id	crossref_primary_10_1054_bjoc_1999_0939 crossref_primary_10_1007_s00280_010_1428_4 crossref_primary_10_1038_sj_bjc_6694381 crossref_primary_10_1007_s11101_011_9222_4 crossref_primary_10_3923_ijp_2008_160_168 crossref_primary_10_1016_j_ntt_2010_09_005 crossref_primary_10_1023_A_1026456926754 crossref_primary_10_1016_j_jinorgbio_2012_08_010 crossref_primary_10_1124_mol_54_1_213 crossref_primary_10_1371_journal_pone_0165062 crossref_primary_10_1089_jwh_1996_5_383 crossref_primary_10_1002_ddr_10421 crossref_primary_10_3390_biom13040595 crossref_primary_10_1002_ijc_25112 crossref_primary_10_3390_toxics3020224 crossref_primary_10_1021_jm031070u crossref_primary_10_1006_gyno_1997_4637 crossref_primary_10_1186_1471_2407_12_200 crossref_primary_10_1023_A_1020403806197 crossref_primary_10_1186_1757_2215_7_45 crossref_primary_10_1002_cbdv_201800373 crossref_primary_10_1016_S0305_7372_97_90032_3 crossref_primary_10_1016_j_bcp_2006_02_011 crossref_primary_10_1016_S0887_2333_99_00082_X crossref_primary_10_1179_135100001101536418 crossref_primary_10_1002_ijc_21675 crossref_primary_10_1111_j_1432_1033_1997_00508_x crossref_primary_10_1016_j_etap_2013_03_023 crossref_primary_10_1016_j_jinorgbio_2006_11_015 crossref_primary_10_1016_S0026_895X_24_13250_6 crossref_primary_10_1128_JVI_77_5_3167_3180_2003 crossref_primary_10_1038_sj_onc_1206933 crossref_primary_10_1016_S1040_8428_00_00053_6 crossref_primary_10_1158_1078_0432_CCR_16_1333 crossref_primary_10_1016_j_bcp_2008_02_023 crossref_primary_10_1158_1078_0432_CCR_06_2770 crossref_primary_10_1007_s12094_007_0096_2 crossref_primary_10_1016_j_phrs_2012_07_005 crossref_primary_10_1016_S0009_2797_99_00115_5 crossref_primary_10_1016_j_mrgentox_2004_05_018 crossref_primary_10_1039_C4MT00112E crossref_primary_10_1097_00001813_200507000_00009 crossref_primary_10_1186_1475_2867_9_4 crossref_primary_10_1002__SICI_1097_0215_19981109_78_4_454__AID_IJC11_3_0_CO_2_6 crossref_primary_10_1016_j_bmc_2014_05_030 crossref_primary_10_1021_jm061219c crossref_primary_10_1155_2011_315418 crossref_primary_10_1158_1078_0432_CCR_07_0164 crossref_primary_10_1007_s00775_013_1003_7 crossref_primary_10_1002_ijc_10132 crossref_primary_10_1088_0031_9155_50_1_008 crossref_primary_10_1016_S0304_3835_98_00175_X crossref_primary_10_1016_j_jinorgbio_2016_06_018
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1007/s002800050413
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID	8599870
Genre	Research Support, Non-U.S. Gov't Journal Article Comparative Study
GroupedDBID	--- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECM EIF EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM 7X8 ADHKG AGQPQ ATHPR
ID	FETCH-LOGICAL-c317t-7228e8c46ff29ea9c20d58dffc749d6c26f21d671487171e3b572c31c4a09d2d2
IEDL.DBID	7X8
ISICitedReferencesCount	83
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10_1007_s002800050413&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0344-5704
IngestDate	Wed Oct 01 14:01:52 EDT 2025 Wed Feb 19 01:12:46 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c317t-7228e8c46ff29ea9c20d58dffc749d6c26f21d671487171e3b572c31c4a09d2d2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	8599870
PQID	77963136
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_77963136 pubmed_primary_8599870
PublicationCentury	1900
PublicationDate	1996-00-00
PublicationDateYYYYMMDD	1996-01-01
PublicationDate_xml	– year: 1996 text: 1996-00-00
PublicationDecade	1990
PublicationPlace	Germany
PublicationPlace_xml	– name: Germany
PublicationTitle	Cancer chemotherapy and pharmacology
PublicationTitleAlternate	Cancer Chemother Pharmacol
PublicationYear	1996
References	1691303 - J Natl Cancer Inst. 1990 May 2;82(9):749-55 3180081 - Cancer Res. 1988 Dec 1;48(23):6703-7 699192 - Chem Biol Interact. 1978 Oct;23(1):99-110 8253089 - EMBO J. 1993 Sep;12(9):3679-84 2742829 - Biochemistry. 1989 Apr 4;28(7):3120-4 8428979 - J Biol Chem. 1993 Feb 15;268(5):3037-9 8402885 - Cell. 1993 Sep 24;74(6):957-67 8430096 - Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):853-7 1638534 - Cancer Res. 1992 Aug 1;52(15):4196-9 1380646 - Mol Cell Biol. 1992 Sep;12(9):3689-98 1847655 - Cancer Res. 1991 Feb 15;51(4):1078-85 2244936 - Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 1327566 - Cancer Metastasis Rev. 1992 Sep;11(2):121-39 3802072 - Cancer Lett. 1987 Jan;34(1):9-13 6245367 - Nature. 1980 Apr 10;284(5756):555-6 8324733 - Cancer Res. 1993 Jul 15;53(14):3237-40 3048763 - Cancer Chemother Pharmacol. 1988;22(4):325-32 1812808 - Annu Rev Genet. 1991;25:229-53 6370067 - Ann Intern Med. 1984 May;100(5):704-13 2653399 - Br J Cancer. 1989 Apr;59(4):527-34 7945400 - Biochem Pharmacol. 1994 Sep 15;48(6):1073-9 1333943 - Cytometry. 1992;13(8):795-808 7971995 - Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10977-81 1614522 - Nature. 1992 Jul 2;358(6381):15-6 8286217 - Br J Cancer. 1994 Jan;69(1):93-100 1517601 - J Immunol Methods. 1992 Aug 30;153(1-2):57-65 7840761 - Bioessays. 1994 Nov;16(11):833-9 2156431 - Am J Pathol. 1990 Mar;136(3):593-608 8137265 - Cancer Res. 1994 Mar 15;54(6):1596-603 6608349 - Biochem Biophys Res Commun. 1984 Jan 30;118(2):392-9 8479522 - Nature. 1993 Apr 29;362(6423):847-9 1526199 - Cytometry. 1992;13(4):416-22 1555236 - Cell. 1992 Apr 3;69(1):119-28 8143768 - Exp Cell Res. 1994 Apr;211(2):231-7 8481916 - Cancer Res. 1993 May 1;53(9):2133-9 2204382 - Cancer Cells. 1990 Feb;2(2):35-43 7014501 - Int Rev Cytol. 1980;68:251-306 8398340 - Eur J Cancer. 1993;29A(3):395-9 1327565 - Cancer Metastasis Rev. 1992 Sep;11(2):105-19 1528325 - Neoplasma. 1992;39(3):189-95 1608949 - Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5408-12 3828995 - Cancer Res. 1987 Apr 15;47(8):2056-61 1677933 - Int Rev Exp Pathol. 1991;32:223-54 1873800 - Cancer Res. 1991 Sep 1;51(17):4557-64 3428045 - Cytometry. 1987 Nov;8(6):637-41 1530564 - Biochem J. 1992 Sep 1;286 ( Pt 2):331-4 1349327 - Int J Radiat Biol. 1992 Apr;61(4):451-3 1647324 - Exp Cell Res. 1991 Jul;195(1):237-46 7919457 - Anticancer Drugs. 1994 Jun;5(3):321-8 1617660 - Cancer Res. 1992 Jul 15;52(14):3857-64 8096193 - FEBS Lett. 1993 Apr 5;320(2):150-4 6682656 - Biochem Biophys Res Commun. 1983 Apr 29;112(2):555-63 1854622 - Br J Cancer. 1991 Jul;64(1):192-6 1933891 - Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 327080 - J Natl Cancer Inst. 1977 Jul;59(1):221-6
References_xml	– reference: 8479522 - Nature. 1993 Apr 29;362(6423):847-9 – reference: 1812808 - Annu Rev Genet. 1991;25:229-53 – reference: 7945400 - Biochem Pharmacol. 1994 Sep 15;48(6):1073-9 – reference: 1933891 - Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 – reference: 1617660 - Cancer Res. 1992 Jul 15;52(14):3857-64 – reference: 3428045 - Cytometry. 1987 Nov;8(6):637-41 – reference: 1647324 - Exp Cell Res. 1991 Jul;195(1):237-46 – reference: 7971995 - Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10977-81 – reference: 8253089 - EMBO J. 1993 Sep;12(9):3679-84 – reference: 1327566 - Cancer Metastasis Rev. 1992 Sep;11(2):121-39 – reference: 6245367 - Nature. 1980 Apr 10;284(5756):555-6 – reference: 1691303 - J Natl Cancer Inst. 1990 May 2;82(9):749-55 – reference: 1608949 - Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5408-12 – reference: 1333943 - Cytometry. 1992;13(8):795-808 – reference: 1555236 - Cell. 1992 Apr 3;69(1):119-28 – reference: 2653399 - Br J Cancer. 1989 Apr;59(4):527-34 – reference: 1380646 - Mol Cell Biol. 1992 Sep;12(9):3689-98 – reference: 8481916 - Cancer Res. 1993 May 1;53(9):2133-9 – reference: 8096193 - FEBS Lett. 1993 Apr 5;320(2):150-4 – reference: 8324733 - Cancer Res. 1993 Jul 15;53(14):3237-40 – reference: 3828995 - Cancer Res. 1987 Apr 15;47(8):2056-61 – reference: 8143768 - Exp Cell Res. 1994 Apr;211(2):231-7 – reference: 6370067 - Ann Intern Med. 1984 May;100(5):704-13 – reference: 6608349 - Biochem Biophys Res Commun. 1984 Jan 30;118(2):392-9 – reference: 1528325 - Neoplasma. 1992;39(3):189-95 – reference: 1349327 - Int J Radiat Biol. 1992 Apr;61(4):451-3 – reference: 8402885 - Cell. 1993 Sep 24;74(6):957-67 – reference: 3048763 - Cancer Chemother Pharmacol. 1988;22(4):325-32 – reference: 1530564 - Biochem J. 1992 Sep 1;286 ( Pt 2):331-4 – reference: 6682656 - Biochem Biophys Res Commun. 1983 Apr 29;112(2):555-63 – reference: 7014501 - Int Rev Cytol. 1980;68:251-306 – reference: 2742829 - Biochemistry. 1989 Apr 4;28(7):3120-4 – reference: 1638534 - Cancer Res. 1992 Aug 1;52(15):4196-9 – reference: 7919457 - Anticancer Drugs. 1994 Jun;5(3):321-8 – reference: 7840761 - Bioessays. 1994 Nov;16(11):833-9 – reference: 1327565 - Cancer Metastasis Rev. 1992 Sep;11(2):105-19 – reference: 1854622 - Br J Cancer. 1991 Jul;64(1):192-6 – reference: 3180081 - Cancer Res. 1988 Dec 1;48(23):6703-7 – reference: 2156431 - Am J Pathol. 1990 Mar;136(3):593-608 – reference: 1526199 - Cytometry. 1992;13(4):416-22 – reference: 8398340 - Eur J Cancer. 1993;29A(3):395-9 – reference: 1873800 - Cancer Res. 1991 Sep 1;51(17):4557-64 – reference: 2204382 - Cancer Cells. 1990 Feb;2(2):35-43 – reference: 699192 - Chem Biol Interact. 1978 Oct;23(1):99-110 – reference: 1614522 - Nature. 1992 Jul 2;358(6381):15-6 – reference: 2244936 - Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 – reference: 3802072 - Cancer Lett. 1987 Jan;34(1):9-13 – reference: 8137265 - Cancer Res. 1994 Mar 15;54(6):1596-603 – reference: 1847655 - Cancer Res. 1991 Feb 15;51(4):1078-85 – reference: 8286217 - Br J Cancer. 1994 Jan;69(1):93-100 – reference: 8430096 - Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):853-7 – reference: 327080 - J Natl Cancer Inst. 1977 Jul;59(1):221-6 – reference: 1517601 - J Immunol Methods. 1992 Aug 30;153(1-2):57-65 – reference: 1677933 - Int Rev Exp Pathol. 1991;32:223-54 – reference: 8428979 - J Biol Chem. 1993 Feb 15;268(5):3037-9
SSID	ssj0004133
Score	1.727845
Snippet	We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	463
SubjectTerms	Antineoplastic Agents - pharmacology Apoptosis Cell Adhesion - drug effects Cell Death Cisplatin - pharmacology DNA, Neoplasm - analysis DNA, Neoplasm - metabolism Drug Resistance, Neoplasm Electrophoresis, Agar Gel Female Flow Cytometry Humans Ovarian Neoplasms - pathology S Phase - drug effects Tumor Cells, Cultured
Title	cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines
URI	https://www.ncbi.nlm.nih.gov/pubmed/8599870 https://www.proquest.com/docview/77963136
Volume	37
WOSCitedRecordID	wos10_1007_s002800050413&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS91AEB9sLaWXam2lttXuoUgLLiabTTYLBRE_qAcf72Dh3R6b_cAc3iaap-DZf9yZJA97KT30khyWCQs7O5nffP0AvgkVSi2V5cEUgUuZZNwolXOf4gKKyErYnmxCTSblbKana_Bz1QtDZZUrm9gbatdYipEfKoWqkmbFUXvDiTOKcqsjgcYLWMcVTTqtZn_MCk8HIvlMSp6rRI4TNvvGuT6jSLNPJPEa_M237P8x5xv_t7tNeDv6lux4UIZ3sObjFry-HLPnW7A_HeZUPxywq-e2q-6A7bPp8wTrh_fwaOuOn9ZmsUA5lL5GUN-0VDUX7xbfLy5-cETyqBOOUdyfOXIj2cj4w0zbtMumqztWR9ZRfTxZVGaiYwjtyV2NS9ZTA7LmHpE6vi0RGsVmYYbvkefbfYDf52dXJ7_4yNbALfogS66EKH1pZRGC0N5oKxKXly4Eq6R2hRVFEKkrFOIvhJCpz6pcCRS10iTaCSe24WVsov8IDFGO80kadBIqRGR5VeTO6DR3QpdVlbkd-Lo6hTneBtqaib656-arc9iB7eEg5-0wtGNe5ggsVfLpn6Kf4c1QmU1hli-wHtAM-F14Ze-XdXe71-sYPifTyyfARd9q
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=cis-Diamminedichloroplatinum%28II%29-induced+cell+death+through+apoptosis+in+sensitive+and+resistant+human+ovarian+carcinoma+cell+lines&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Ormerod%2C+M+G&rft.au=O%27Neill%2C+C&rft.au=Robertson%2C+D&rft.au=Kelland%2C+L+R&rft.date=1996-01-01&rft.issn=0344-5704&rft.volume=37&rft.issue=5&rft.spage=463&rft_id=info:doi/10.1007%2Fs002800050413&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon